Paris, 01/12/2025. METHYS Dx, a company with pioneering liquid biopsy solutions based on methylation signatures, announced today it had entered into a distribution agreement with CliniSciences. This agreement will enable the large-scale commercialization of METHYS Dx M*Detect kits for digital PCR in RUO (Research Use Only) format across Europe, North America and North Africa. METHYS […]
> Read more
Valerie Taly will give a keynote lecture at the European Digital PCR Symposium (18-19 Nov) organized by the Ghent University Digital PCR Center and coordinated by Wim Trypsteen and Ward Despiegelaere. With a cutting-edge program this symposium (followed by a workshop organised in the Digital PCR center) will be a great opportunity to discuss last […]
> Read more
13/10/2025 – METHYS Dx is proud to join forces with Geeng Genetic Genius in a strategic partnership aimed at enhancing the integration of innovative technologies in diagnostic applications. Alongside Geeng, METHYS Dx brings its expertise in liquid biopsy to this shared ambition, delivering more agile, personalized, and clinically relevant diagnostic solutions for patients. A big […]
> Read more
10/10/2025 – Valerie Taly will give a lecture entitled “Methylation markers and digital PCR for cancer patient follow-up” as part of the EMBL Heidelberg course on Liquid Biopsies. This EMBL course on Liquid Biopsies, aimed for students and early-career researchers, is coordinated by Drs Anders Ståhlberg and Martin Dalin (University of Gothenburg), along with Sophie […]
> Read more
Valerie Taly will give a talk on Methylation Based Biomarkers & Digital PCR for Cancer Patient Follow-up October 1st at the Biomarkers & Precision Medicine 2025 conference in London ! Valérie will be sharing our latest insights on the follow-up of several cancers, her presentation will take place in Conference Room 4, on October 1st […]
> Read more
19/09/2025 – METHYS Dx has been selected to join the Paris Saclay Cancer Cluster (PSCC) BOOST program. METHYS Dx is delighted to have been selected alongside 8 other innovative start-ups in the field of oncology! Congratulations to the other selected start-ups sélectionnées : BiPER Therapeutics, CYBERNA, 𝗟𝗮𝗳𝗮𝗺𝗲, 𝗡𝗮𝗻𝗼𝗞𝘂𝗿 , Peekcell , 𝗦𝗽𝗶𝗰𝗲 𝗕𝗶𝗼, Syntopia and […]
> Read more
27/05/2025 – METHYS Dx had the honor of pitching in front of a panel of venture capital investors at GO Invest Start-up, an event organized by the Paris Île-de-France Regional Chamber of Commerce and Industry and La French Tech Grand Paris. METHYS Dx is delighted to have received the “prix coup de cœur du jury” […]
> Read more
04/2025 – Following our i-Lab Grand Prize in 2023, Les Deeptech and Bpifrance created a wonderful feature about our company! Many thanks to them! See the video here!
> Read more
19/03/2025 – METHYS Dx has been selected by a jury of experts for the Healthtech Innovation Program Neighborhood of Voisin Consulting Life Sciences (VCLS). Thanks to this program METHYS Dx will beneficiate from the expertise of Voisin Consulting Life Sciences (VCLS) and their large network of experts. The neighborhood program will procure personalized mentoring to […]
> Read more
Valérie Taly has been selected to join the 8th cohort of the Women Leadership Programme of the European Innovation Council (EIC). This programme, initiated by the European Innovation Council (EIC) in partnership with the European Institute of Innovation and Technology (EIT) and the European Innovation Council and SMEs Executive Agency (EISMEA) aims to strengthen the leadership […]
> Read more
16/09/2024 – METHYS Dx is thrilled to announce Valérie Taly (President and CSO) and Magali Droniou (COO) are part of thewinners of the new 2024 Women TechEU EU-funded program! It is a great honor for Valérie, Magali and METHYS Dx to be part of the 40 women-led Deep tech selected start-ups over more than 800 […]
> Read more
05/07/ 2023 – We are proud to announce that METHYS Dx is laureate of one of the 10 Grand Prix of the I-Lab innovation competition 2023! Many thanks to the French governement, ADEME and Bpifrance for their support #France2030! And bravo for this great awards event at Châtelet theater !! We would like to thank […]
> Read more
29/06/2023 – Magali Droniou, PhD, Chief Operating Officer at METHYS Dx, was appointed General Director by the company’s shareholders on June 29, 2023. Magali Droniou brings to METHYS Dx a unique expertise at the intersection of scientific research, technological innovation, and strategic development. PhD in molecular biology, she has led an international academic research career […]
> Read more
15/06/2023 – Two new directors have joined METHYS Dx this month: Dr. Antoine Masurier as Chief Technology Officer, and Dr. Jean-François Taly as Director of Bioinformatics & IT. Engineer from Chimie ParisTech and PhD holder in Molecular Biology from Université Paris Sciences et Lettres, Antoine has been working since 2021 on an innovative detection technology […]
> Read more
07/12/2022 – Valérie Taly, PhD, HDR, Research Director first class (DR1) at CNRS, co-founder of METHYS Dx and Chief Scientific Officer, was appointed President of METHYS Dx on December 7, 2022, by the company’s shareholders.
> Read more
17/11/2022 – Do not miss the presentations “Droplet-based Microfluidics to Detect Cancer Biomarkers” & “Developing Original Droplet-based Digital PCR Assays to Detect Circulating Biomarkers” by Valérie Taly, CNRS Research Director, as Plenary and Keynote Speaker on December 14 at 2:30 p.m. and December 16 at 4:30 p.m.!
> Read more
16/11/2022 – We are very happy to announce that METHYS Dx has been selected to join the new promotion of the @WILCO #MedTech program. We are proud to join this #accelerator of innovation which supports #startups until their 1rst M€ of annual revenue in 3 years and the transformation of ETI / Key Accounts. We […]
> Read more
15/09/2022 – We are happy to announce that METHYS Dx has been awarded the French Tech Emergence Grant by the BPI, to accelerate its R&D!! About BPIFrance – French Tech Emergence The BPI France French Tech Emergence Grant finances the analysis of the potential of a breakthrough innovation project as well as its market prospects. […]
> Read more